No telehealth platform changes how a drug works. Semaglutide, tirzepatide and orforglipron produce the same pharmacology whoever writes the prescription. The differences that survive scrutiny are which labeled product a program tends to route toward, whether structured coaching sits alongside the prescription, and whether the dispensed product has trial evidence attached to it at all.
Three mechanisms, not one
Semaglutide is a GLP-1 receptor agonist. Tirzepatide activates both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide receptor, a dual mechanism described in the peer-reviewed literature on incretin pharmacology. Orforglipron is an orally administered small-molecule GLP-1 receptor agonist rather than a peptide, which is why it can be taken as a tablet without the absorption workarounds peptide formulations require.
Those distinctions matter because programs increasingly offer several of them. Ro publishes access to pen and pill forms across multiple approved products. Calibrate’s materials name tirzepatide, semaglutide and dulaglutide by molecule and then list the brand names members may recognize. Hims and Hers moved to approved brand semaglutide products during 2026. A member choosing between platforms is often choosing between similar menus.
It helps to remember that most of these companies sell well beyond weight medication. Hims and Hers and Ro both built their early businesses on sexual health, and providers such as HealthRX run a separate ED treatment line next to their metabolic offerings, while Henry Meds and Calibrate stay closer to a single category. For a weight-loss shopper the lesson is that a familiar brand name says nothing about which molecule reaches the door or whether it carries trial evidence.
What the labels actually authorize
This is where a checkable difference appears, and it is routinely blurred in marketing. On DailyMed, Zepbound is indicated to reduce excess body weight and maintain weight reduction long term in adults with obesity or overweight plus a weight-related condition, and separately to treat moderate to severe obstructive sleep apnea in adults with obesity. Foundayo, the orforglipron tablet, carries a weight reduction and maintenance indication. The current Wegovy label covers both injection and tablet forms.
Mounjaro, by contrast, is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged ten and older with type 2 diabetes. Ozempic sits in the diabetes column too. Programs that list Ozempic or Mounjaro among weight loss options are describing prescribing that sits outside the weight-management indication, which is lawful clinical practice but changes how a prior authorization is likely to be evaluated.
The trial evidence belongs to the molecules
Expected results should be read off the trial record, not off a platform’s landing page. STEP 1 tested once-weekly semaglutide in adults with overweight or obesity. SURMOUNT-1 tested once-weekly tirzepatide in a separate population under a separate protocol. These were different trials, and placing their headline percentages side by side is a cross-trial comparison rather than a head-to-head result. A later randomized comparison of the two agents exists and is the more defensible reference when a direct contrast is needed.
Maintenance data is where expectations usually break. The STEP 4 trial examined what happened when semaglutide was continued versus withdrawn after an initial run-in, and SURMOUNT-4 asked a parallel question for tirzepatide. A published extension of STEP 1 documented weight regain and reversal of cardiometabolic improvements after treatment stopped. None of that is platform-specific. It is the property of the drug class, and any program promising durable results without addressing continuation is describing something the evidence does not support.
Where a coaching wrapper has its own evidence
Calibrate positions itself around metabolic health rather than a prescription alone, pairing the drug with short one-to-one video coaching sessions on a recurring cadence, a structured curriculum and baseline laboratory work. That is a genuinely different product shape from a medication-first platform, and the question worth asking is whether the wrapper adds measurable effect.
The literature offers partial answers. The STEP 3 trial studied semaglutide added to intensive behavioral therapy, which is a considerably more demanding intervention than periodic check-ins. Randomized work on adaptive behavioral weight management and a 2025 trial comparing an artificial-intelligence lifestyle intervention against human coaching in a diabetes prevention setting both point to behavioral support producing real but modest effects relative to pharmacotherapy. Reviews of adherence to GLP-1 therapy suggest structured nutritional and lifestyle support tracks with staying on treatment, which may be where coaching earns its keep.
Cost sits on the other side of that ledger. A coaching-inclusive membership is buying clinician time, curriculum and benefits work, while a flat cash program buying clinician oversight and medication together, of the kind published by Henry Meds, Mochi Health and formblends.com, is buying less service for a lower and more predictable number. Those programs typically dispense compounded preparations, which the FDA has not reviewed for safety, effectiveness or manufacturing quality, so the trial evidence above attaches to the molecule rather than to the specific product shipped.
| Evidence question | Coaching and navigation model | Medication-first telehealth |
|---|---|---|
| Primary driver of weight change | Prescribed GLP-1 or dual agonist | Prescribed GLP-1 or dual agonist |
| Products commonly named | Semaglutide, tirzepatide, dulaglutide by molecule | Approved brand pens and tablets by product name |
| Indication alignment | Mixed, since some named brands carry diabetes labeling | Mixed, depending on which product is dispensed |
| Behavioral component | Recurring short coaching sessions plus curriculum | Messaging and check-ins around dose management |
| Evidence for the wrapper | Behavioral trials show real but modest independent effect | Little independent evidence claimed for the wrapper |
| Maintenance handling | Program phases extend past the first year | Continuation depends on renewal and supply |
Frequently asked questions
Will the same drug work better through one platform than another?
No. Pharmacology does not vary by vendor. What varies is which product is dispensed, whether the dose reaches the maintenance level studied in trials, and whether the person stays on treatment long enough for that dose to matter. Those are logistics and adherence questions, and they are where platforms genuinely differ.
Is tirzepatide simply stronger than semaglutide?
The trials most often quoted were run separately with different populations and protocols, so stacking their headline numbers is not a valid comparison. A randomized head-to-head study of the two agents in adults with overweight or obesity exists and is the appropriate reference. Individual response varies widely regardless of which molecule the average favors.
Does adding coaching change expected results?
Modestly, based on the behavioral literature rather than on any platform claim. Structured lifestyle support has measurable effects on adherence and on outcomes, and trials pairing medication with intensive behavioral therapy show additive benefit. The medication remains the dominant term in the equation, and coaching should be valued as support rather than as a second drug.
What happens to results after treatment stops?
Published withdrawal and continuation trials show substantial weight regain and reversal of cardiometabolic gains once therapy ends. Newer reviews frame discontinuation as a physiological and follow-up problem rather than a personal failure. Any comparison of these programs should include what each one does when a member wants to taper or stop.
By
